Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

Cutaneous T-Cell Lymphoma/Mycosis Fungoides Clinical Trial

Official title:
A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)

Status Completed

Clinical Trial Summary

Single center, pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Mycoses
Mycosis Fungoides

Clinical Trial Details

NCT number	NCT04702503
Study type	Interventional
Source	Moleculin Biotech, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	March 8, 2019
Completion date	November 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03837457` - PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study	Phase 2
Completed	`NCT05380635` - PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma	Phase 2
Not yet recruiting	`NCT06113081` - Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Recruiting	`NCT06149247` - HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL	Phase 2
Terminated	`NCT03713320` - SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides	Phase 2